Media Coverage

AgriLabs, Epitopix put first Klebsiella mastitis vaccine on US market

Jul 25, 2018 - Animal Pharm
By Joseph Harvey

AgriLabs has commercialized Epitopix's KLEBVax SRP in the US – the first vaccine licensed for dairy cattle to prevent mastitis caused by Klebsiella pneumoniae.

In a field study, KLEBVax SRP reduced incidence of infection by 71% versus a placebo within 90 days of calving.

Klebsiella has been difficult to prevent in dairy operations and has significantly upped costs in the US cattle industry, the company noted. Klebsiella pneumoniae mastitis causes cattle production losses and death due to intramammary infection at higher rates when compared to the disease caused by E coli.

St Joseph, Missouri-based AgriLabs previously sold a similar vaccine offered as an autogenous product through a partnership struck with Epitopix in 2014.

The vaccine incorporates the Epitopix's Siderophore Receptor and Porin (SRP) technology. AgriLabs said: "Gram-negative bacteria such as Klebsiella require iron for growth and survival. Using SRP technology, KLEBVax activates the animal's immune system to produce antibodies that bind and block the transfer of iron through bacterial cell wall porins, starving the bacteria of needed nutrients."

Jim Sandstrom, managing director of Epitopix, explained: "The unique process of the SRP technology makes it well-suited for the challenges associated with disease-causing bacteria such as Klebsiella. With several years of field experience with autogenous Klebsiella SRP vaccines, we are confident the new KLEBVax SRP product will help dairy veterinarians and producers manage mastitis infections caused by Klebsiella."

The two companies teaming up to bring KLEBVax SRP to market have both been recently acquired. AgriLabs is now part of Huvepharma, while Minnesota-headquartered Epitopix was purchased by Dutch company Vaxxinova earlier this year.

Reprinted with permission of Animal Pharm News




Tweet @AHCorridor

News Releases

The Connector

KC Animal Health Blog